目前关于Cabazitaxel治疗前列腺癌的证据:叙述性审查
Kazuhiro Suzuki1, Hideyasu Matsuyama2, Nobuaki Matsubara3
1Department of Urology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
概括
卡巴西塔克塞尔在先前治疗后对转移性割抵抗性前列腺癌 (mCRPC) 有效. 管理中性质减退是优化cabazitaxel在前列腺癌治疗中的有效性和安全性的关键.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在日本,前列腺癌 (PC) 发病率正在上升.
- 雄激素剥夺疗法 (ADT) 是割敏感PC (CSPC) 的标准,但耐药性导致转移性割耐药PC (mCRPC).
- 基于taxane的疗法 (docetaxel,cabazitaxel) 是mCRPC的主要支柱.
研究的目的:
- 审查基于税的疗法的证据,重点关注日本患者的cabazitaxel.
- 为了解决与转移性CSPC (mCSPC) 中的雄激素受体信号传导抑制剂 (ARSIs) 的税的演变作用和序列.
- 为了确定受益于基于税的治疗的患者群体.
主要方法:
- 对基于税的疗法,特别是cabazitaxel的临床和现实世界的证据的审查.
- 在mCSPC新ARSI组合的背景下对治疗顺序的分析.
- 评估cabazitaxel的疗效和安全性,包括中性质衰竭的管理.
主要成果:
- 卡巴西塔克塞尔在mCRPC患者中显示出有效性,他们先前接受了ARSI和多塞塔克塞尔治疗,表现优于第二次ARSI (CARD研究).
- 卡巴西塔克塞尔的安全性,特别是中性,可以通过G-CSF预防,剂量调整和间隔变化来控制.
- 中性发育不良可能是治疗有效性的预后指标,需要适当的剂量强度.
结论:
- 卡巴西塔克塞尔是重度预治疗的mCRPC患者的一个有价值的选择.
- 在mCSPC中对税和ARSI的最佳测序需要进一步的研究.
- 了解PC生物学和收集现实数据对于改善治疗结果和安全至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:27Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463